Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 12/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163657 | 1.00 | POLB (0.41) | POLBGAAMAPTALDH1A1GPR84 | |
| SCHEMBL25025146 | 1.00 | POLB (0.41) | POLBGAAMAPTALDH1A1GPR84 | |
| SCHEMBL8592976 | 0.93 | MAPT (0.43) | POLBGAAMAPTALDH1A1TSHR | |
| SCHEMBL31163671 | 0.91 | PPARA (0.41) | — | |
| SCHEMBL10058640 | 0.91 | PPARA (0.41) | — | |
| SCHEMBL31225285 | 0.87 | GAA (0.42) | POLBGAAMAPTALDH1A1GPR84 | |
| SCHEMBL14546802 | 0.85 | GAA (0.45) | POLBGAAMAPTALDH1A1TSHR | |
| SCHEMBL16707337 | 0.84 | EPHX1 (0.39) | MAPTALDH1A1GPR84 | |
| SCHEMBL22878973 | 0.84 | EPHX1 (0.39) | MAPTALDH1A1GPR84 | |
| SCHEMBL12165247 | 0.80 | GAA (0.39) | POLBGAAMAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163477-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LIMITED (HK) | 2021-06-03 | — | — | US | disclosed |
| WO-2020160054-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | CANWELL BIOTECH LIMITED (CN) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163477-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | TLR8, TLR7, TLR1 | POLB 2799/4885GAA 3452/4885MAPT 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.